Work

EE464 The Cost-Effectiveness of Subcutaneous Semaglutide 2.4MG Injection in the Management of Obesity in Canada Using the Core Obesity Model

Year: 2022

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2022.04.712

Authors: AV Olivieri, S Larsen, M Luckevich, K Chan, M Lamotte

Institutions: Novo Nordisk (Denmark), Novo Nordisk Canada (Canada)

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4283515565

Cites:

Cited by: 3

Related to: 10